Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS: Encorafenib + Binimetinib in Melanoma Brain Metastasis
NCT03911869Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of encorafenib and binimetinib in melanoma (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Brain Metastasis Response Rate Based on Modified Response Evaluation Criteria in Solid Tumors Version 1.1 up to 8.3 months and 1 more. Started Apr 2019; status: terminated.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03911869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911869.